Zhou DX, Jiang SW, Zhang CG, Cai BJ, Lv HD. Perioperative SOX plus sintilimab vs P-SOX and CAPOX in advanced gastric cancer: A real-world comparison. World J Gastroenterol 2026; 32(29): 119809 [DOI: 10.3748/wjg.119809]
Corresponding Author of This Article
Hai-Dong Lv, Professor, Department of Gastrointestinal Cancer Surgery, Qinghai Provincial People’s Hospital, No. 2 Gonghe Road, Chengdong District, Xining 810000, Qinghai Province, China. lvhaid@126.com
Research Domain of This Article
Oncology
Article-Type of This Article
research-article
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Zhou DX, Jiang SW, Zhang CG, Cai BJ, Lv HD. Perioperative SOX plus sintilimab vs P-SOX and CAPOX in advanced gastric cancer: A real-world comparison. World J Gastroenterol 2026; 32(29): 119809 [DOI: 10.3748/wjg.119809]
Di-Xia Zhou, Hai-Dong Lv, Department of Gastrointestinal Cancer Surgery, Qinghai Provincial People’s Hospital, Xining 810000, Qinghai Province, China
Shao-Wei Jiang, Department of Radiation Oncology, Qinghai University Affiliated Hospital, Xining 810000, Qinghai Province, China
Chen-Guang Zhang, School of Clinical Medicine, Qinghai University, Xining 810000, Qinghai Province, China
Bao-Jia Cai, Department of Gastrointestinal Oncology, Qinghai University Affiliated Hospital, Xining 810000, Qinghai Province, China
Co-first authors: Di-Xia Zhou and Shao-Wei Jiang.
Author contributions: Zhou DX and Jiang SW were responsible for study conception and design, data analysis, and manuscript drafting, contributed equally as co-first authors; Zhang CG and Cai BJ contributed to data collection and interpretation; Lv HD supervised the study and revised the manuscript critically for important intellectual content. All authors approved the final version of the manuscript.
AI contribution statement: DeepSeek(V3) was used during manuscript preparation. DeepSeek was used only for language polishing and translation assistance. It was not used for data analysis, statistical analysis, or scientific writing assistance.
Institutional review board statement: This study was approved by the Ethics Committee of the Qinghai University Affiliated Hospital, No. SL-2022-035.
Informed consent statement: Written informed consent was obtained from all participants.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: The data supporting the findings of this study are available from the corresponding author upon reasonable request, subject to institutional and ethical regulations.
Corresponding author: Hai-Dong Lv, Professor, Department of Gastrointestinal Cancer Surgery, Qinghai Provincial People’s Hospital, No. 2 Gonghe Road, Chengdong District, Xining 810000, Qinghai Province, China. lvhaid@126.com
Received: February 6, 2026 Revised: February 25, 2026 Accepted: March 27, 2026 Published online: August 7, 2026 Processing time: 161 Days and 14.7 Hours
Core Tip
Core Tip: This real-world study systematically compared perioperative oxaliplatin plus S-1 combined with sintilimab, nab-paclitaxel plus oxaliplatin and S-1, and capecitabine plus oxaliplatin regimens in patients with advanced gastric cancer, focusing on treatment efficacy, survival outcomes, and safety. Beyond conventional survival analyses, a prognostic model was developed and validated to stratify progression-free survival risk using readily available clinicopathological and treatment response variables. The findings demonstrate that oxaliplatin plus S-1 combined with sintilimab is associated with favorable survival outcomes with manageable toxicity, and the proposed nomogram provides a practical tool for individualized risk assessment and treatment decision-making in perioperative advanced gastric cancer.
